Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Actuate Therapeutics, Inc. - Common stock (ACTU)
Company Research
Source: GlobeNewswire
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3ß), today announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. In addition, the management team will be available for one-on-one meetings during the conference. Details on the presentation: Format: Corporate Presentation Date: Tuesday, September 10, 2024 Time: 4:00 PM ET Webcast Link: click here The webcast of the presentation will be accessible in the Investor section of the Actuate website About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on d
Show less
Read more
Impact Snapshot
Event Time:
ACTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACTU alerts
High impacting Actuate Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ACTU
News
- Actuate Therapeutics to Participate in Upcoming Investor Conferences in FebruaryGlobeNewswire
- Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
- Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic CancerGlobeNewswire
- Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic CancerGlobeNewswire
- Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
ACTU
Sec Filings
- 2/7/25 - Form 8-K
- 12/17/24 - Form 8-K
- ACTU's page on the SEC website